Amphotericin B-resistant Aspergillus flavus infection successfully treated with caspofungin, a novel antifungal agent.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 12063497.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Invasive aspergillosis is uncommon in immunocompetent hosts but is the second most common opportunistic fungal infection in immunocompromised patients. There has been a dramatic increase in the incidence of life-threatening aspergillosis during the past 2 decades, and the morbidity and mortality of these infections despite antifungal therapy remain unacceptably high. We describe a patient with amphotericin B-resistant Aspergillus flavus successfully treated with caspofungin, an agent belonging to a new class of antifungal drugs. Caspofungin shows great promise in the treatment of invasive aspergillosis.
Medical subject headings
- Amphotericin B
- Anti-Bacterial Agents
- Antifungal Agents
- Aspergillosis
- Aspergillus flavus
- Drug Resistance, Fungal
- Peptides
- Peptides, Cyclic